Bronchopulmonary Dysplasia, Prematurity, Respiratory Distress Syndrome in Premature Infant
Conditions
Keywords
Bronchopulmonary dysplasia, Respiratory Distress Syndrome in premature infant, Prematurity, Lung injury, Poractant alfa, Pulmonary surfactant, Budesonide, Anti-inflammatory agents, Glucocorticoids, Lung ultrasound, IL-6
Brief summary
This study is designed to determine whether intratracheal administration of budesonide combined with surfactant, as compared to surfactant alone, will modify ecographic (lung ultrasound score) and biological markers (IL-6 concentration in respiratory secretions) at 7 days of life in preterm infants ≤32 weeks of gestational age (GA).
Detailed description
Bronchopulmonary dysplasia (BPD) is one of the main morbidities associated with extreme prematurity and, despite the improvement of respiratory care in the latest years, overall incidence is not decreasing. Etiology of BPD is multifactorial and local inflammation plays an important role in it, therfore, local anti-inflammatory drugs could be effective in preventing BPD. Recent randomised trials have shown a lower incidence of BPD/death with the use of a combination of budesonide with surfactat compared to surfactant alone, and further clinical trials are currently ongoing. This is a controlled phase IV, randomised, unicenter clinical trial designed to evaluate the effect of intratracheal administration of budesonide combined with surfactant, as compared to surfactant alone, in BPD in preterm infants ≤32 weeks of GA. Investigators will compare ecographic and biological markers, as well as respiratory outcomes.
Interventions
Poractant alfa (Curosurf®): First dose of treatment: 200mg/Kg. Further doses (up to a total maximum of 3 within first 48 hours of life): 100mg/Kg.
Poractant alfa (Curosurf®) + Budesonide nebulizer solution (Budesonida Aldo-Unión 0.5mg/mL suspensión para inhalación por nebulizador®): First dose: 200mg/Kg of surfactant + 0.25mg/Kg of budesonide. Further doses (up to a total maximum of 3 within first 48 hours of life): 100mg/Kg of surfactant + 0.25mg/Kg of budesonide.
Sponsors
Hospital Clinic of Barcelona
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)
Masking description
When eligibility of an infant is confirmed, consent will be obtained. Infants candidates to surfactant administration will be randomly assigned to either receive surfactant with budesonide, or surfactant alone, using a web-based randomisation system with an allocation ratio of 1:1. Primary care provider in charge of the patient at the time of the enrolment will be responsible for the randomization, and for the preparation of the drug (surfactant alone, or surfactant with budesonide). Participants will be masked.
Intervention model description
This is a randomised trial. Infants who fit criteria for surfactante administration will be randomly assigned into 2 groups: Standard treatment group receiving only intratracheal surfactant, and Interventional treatment group receiving intratracheal surfactant combined with budesoinde. It will be a third group of patients ≤32 weeks (Control group) who won´t fit criteria for surfactant administration.
Eligibility
Sex/Gender
ALL
Age
No minimum to 48 Hours
Healthy volunteers
No
Inclusion criteria
* Infants born equal or earlier than 32 weeks of gestational age admitted in the Neonatal Intensive Care Unit. * Parental consent signed. * Less than or equal to 48 hours postnatal age.
Exclusion criteria
* Infants with known major congenital anomalies (eg. congenital upper airwayobstruction, congenital lung anomaly, severe pulmonary hypoplasia, hydrops,neuromuscular diseases, chromosomopaties) * Infants with poor prognosis and risk of imminent death * Infants who have received the first dose of surfactant before of the enrolment to the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Lung ultrasound score at 7 days of life. | 7 days of life | LUS will be performed with the patients in supine position and slightly lying on the side of the taken view. Each lung will be divided in five areas through longitudinal orientation and images will be taken using the linear probe (VF 13-5MHz). |
| IL-6 concentration in respiratory secretions at 7 days of life. | 7 days of life | Nasopharyngeal aspirate (NPA) will be collected by standard procedure. IL-6 concentration will be determined by Human IL-6 Quantikine ELISA (R&D Systems Inc., Minneapolis, MN, USA). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of days of oxygen | 7 and 28 days of age, 36 weeks of post-menstrual age. | Number of days on FiO2 \>21% supplied by any respiratory support |
| Number of days of respiratory support | 7 and 28 days of age, 36 weeks of post-menstrual age. | Number of days on each level of respiratory support: * No respiratory support * Nasal cannula at flow rates ≤ 2L/min * Nasal cannula at flow rates \> 2L/min * CPAP/BIPAP * Invasive mechanical ventilation |
| Lung ultrasound score at 28 days of life. | 28 days of life | LUS will be performed with the patients in supine position and slightly lying on the side of the taken view. Each lung will be divided in five areas through longitudinal orientation and images will be taken using the linear probe (VF 13-5MHz). |
| Incidence of bronchopulmonary dysplasia | 36 weeks of post-menstrual age. | BPD will be defined according to the 2001 workshop definition (Jobe AH, Bancalari E. Bronchopulmonary dysplasia. American Journal of Respiratory and Critical Care Medicine. American Lung Association; 2001; pp 1723-9). |
| Respiratory status and neurodevelopment | 24 months of age. | Neurodevelopment will be assessed using Bayley-III test. |
| Mean airway pressure (MAP) | 7 and 28 days of age, 36 weeks of post-menstrual age. | Maximum MAP mesured in cmH2O at 7 and 28 days of age, 36 weeks of postmenstrual age. |
| IL-6 concentration in respiratory secretions at 28 days of life. | 28 days of life | Nasopharyngeal aspirate (NPA) will be collected by standard procedure. IL-6 concentration will be determined by Human IL-6 Quantikine ELISA (R&D Systems Inc., Minneapolis, MN, USA). |
Contacts
Primary ContactMarta Teresa-Palacio, MD
Outcome results
None listed